تداخلات ليثيوم

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة البلادونا والأفيون، التداخلات الدوائية)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة أمفيتامين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (نشرة أمفيتامين وديكستروأمفيتامين، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

Table 5: Amiodarone Drug Interactions Concomitant Drug Class/Name Examples Clinical Comment QT Prolonging Drugs class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents Increased risk of Torsade de Pointes. (نشرة أميودارون، التداخلات الدوائية)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (نشرة أوكسيكودون، التداخلات الدوائية)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة أوكسيمورفون، التداخلات الدوائية)

For specific information about the contraindications of lithium or valproate, refer to the Contraindications section of the package inserts for these other products. (نشرة أولانزابين، موانع الاستعمال)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة أوليسيريدين، التداخلات الدوائية)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة باراسيتامول وكودايين، الاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بروميثازين وكودايين، التداخلات الدوائية)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة بنتازوسين ونالوكسون، الاحتياطات)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوبرينورفين، التداخلات الدوائية)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة بوبرينورفين ونالوكسون، التداخلات الدوائية)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، التداخلات الدوائية)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة بوتالبيتال وباراسيتامول وكافيين وكودايين، التداخلات الدوائية)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة بوتورفانول، الاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (نشرة ديكستروأمفيتامين، التحذيرات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة ريميفنتانيل، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة زيبراسيدون، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة فنتانيل، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

Avoid concomitant use with lithium. (نشرة فوروسيميد، التداخلات الدوائية)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة كودايين، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة ليسديكسامفيتامين، التحذيرات والاحتياطات)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة ليفورفانول، الاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة مورفين، التداخلات الدوائية)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (نشرة ميتاكسالون، التداخلات الدوائية)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (نشرة ميثادون، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة ميثامفيتامين، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

الجمع بين نبتة سانت جون ومضادات الاكتئاب والأدوية السيروتونينية الأخرى يزيد خطر متلازمة السيروتونين. (NCCIH, St. John's Wort)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون، التداخلات الدوائية)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة هيدروكودون وإيبوبروفين، الاحتياطات)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (نشرة هيدروكودون وباراسيتامول، الاحتياطات)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون وكلورفينيرامين، التداخلات الدوائية)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدروكودون وهوماتروبين، التداخلات الدوائية)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (نشرة هيدرومورفون، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (نشرة ليثيوم، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, tramadol, tryptophan, buspirone, and St. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Lithium: Risk of lithium toxicity. (نشرة إربيسارتان، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

Lithium: Increases in serum lithium concentrations and lithium toxicity. (نشرة أزيلسارتان، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

مكملات الكالسيوم قد تقلّل امتصاص هذه الأدوية؛ افصل بينها بعدة ساعات. (NIH Office of Dietary Supplements, Calcium)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (نشرة ليثيوم، التداخلات الدوائية)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (نشرة ليثيوم، التداخلات الدوائية)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (نشرة ليثيوم، التداخلات الدوائية)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (نشرة ليثيوم، التداخلات الدوائية)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (نشرة ليثيوم، التداخلات الدوائية)

Amiloride may be considered as a therapeutic agent for lithium-induced nephrogenic diabetes insipidus. (نشرة ليثيوم، التحذيرات والاحتياطات)

Lithium Theophylline increases renal lithium clearance. (نشرة أمينوفيلين، التداخلات الدوائية)

Monitor serum lithium levels frequently ( 7.4 ). (نشرة إنالابريل، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Lithium Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. (نشرة إنالابريلات، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. (نشرة إنسولين أسبارت، التداخلات الدوائية)

Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. (نشرة إنسولين ديتيمير، التداخلات الدوائية)

Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. (نشرة إنسولين ديغلوديك، التداخلات الدوائية)

Alcohol, Beta-blockers, Clonidine, and Lithium Salts Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically indicated, when used concomitantly with these drugs. (نشرة إنسولين عادي (بشري)، التداخلات الدوائية)

Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. (نشرة إنسولين غلارجين، التداخلات الدوائية)

Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. (نشرة إنسولين ليسبرو، التداخلات الدوائية)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Lithium: Increases in serum lithium concentrations and lithium toxicity ( 7.4 ). (نشرة أولميسارتان، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (نشرة ليثيوم، التحذيرات والاحتياطات)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, tramadol, tryptophan, buspirone, and St. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Decreased absorption of lithium and thyroxine have also been reported with co-administration of Sodium Polystyrene Sulfonate Powder, for Suspension. (نشرة بوليستيرين سلفونات الصوديوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Lithium: Increase serum lithium levels, symptoms of lithium toxicity. (نشرة بيريندوبريل، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

Lithium: Symptoms of lithium toxicity ( 7.6 ) (نشرة بينازيبريل، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. (نشرة تراندولابريل، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

Monitor lithium levels if lithium is used with high-dose topiramate extended-release ( 7.7 ) (نشرة توبيرامات، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (نشرة ليثيوم، التحذيرات والاحتياطات)

Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including telmisartan. (نشرة تيلميسارتان، التداخلات الدوائية)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Lithium: Monitor serum lithium concentrations ( 7.1 ) (نشرة تينيدازول، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

May lower theophylline seizure threshold Lithium Theophylline increases renal lithium clearance. (نشرة ثيوفيلين، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (نشرة درونابينول، التحذيرات والاحتياطات)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (نشرة ليثيوم، التداخلات الدوائية)

Lithium: Use with caution (7.4). (نشرة راميبريل، التداخلات الدوائية)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (نشرة ليثيوم، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

Lithium: Increased risk of lithium toxicity. (نشرة ساكوبيتريل وفالسارتان، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Drugs Suspected of Causing Diabetes Insipidus Use with drugs suspected of causing diabetes insipidus (e.g., demeclocycline, lithium, foscarnet, clozapine) may decrease the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (نشرة فازوبريسين، التداخلات الدوائية)

Lithium: Increases in serum lithium level and lithium toxicity ( 7.4 ) (نشرة فالسارتان، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. (نشرة فوسينوبريل، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (نشرة ليثيوم، التداخلات الدوائية)

Neuromuscular Blocking Agents Clinical Impact: Lithium may prolong the effects of neuromuscular blocking agents. (نشرة ليثيوم، التداخلات الدوائية)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (نشرة ليثيوم، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, tramadol, tryptophan, buspirone, and St. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Methyldopa, Phenytoin and Carbamazepine Clinical Impact: Concomitant use may increase risk of adverse reactions of these drugs. (نشرة ليثيوم، التداخلات الدوائية)

Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. (نشرة كابتوبريل، التداخلات الدوائية)

Methyldopa, Phenytoin and Carbamazepine Clinical Impact: Concomitant use may increase risk of adverse reactions of these drugs. (نشرة ليثيوم، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

Concomitant use of calcitonin salmon and lithium may lead to a reduction in plasma lithium concentrations due to increased urinary clearance of lithium. (نشرة كالسيتونين السلمون، التداخلات الدوائية)

Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor Clinical Impact: Concomitant use of lithium with an SGLT2 inhibitor may decrease serum lithium concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Lithium: Increases in serum lithium concentrations and toxicity ( 7 ). (نشرة كانديسارتان، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (نشرة كلوريد الكالسيوم، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. (نشرة كينابريل، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

Lithium: Risk of lithium toxicity. (نشرة لوسارتان، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

Lithium: Symptoms of lithium toxicity ( 7.5 ) (نشرة ليزينوبريل، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (نشرة ليثيوم، التحذيرات والاحتياطات)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (نشرة ليثيوم، التحذيرات والاحتياطات)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (نشرة ليثيوم، التحذيرات والاحتياطات)

Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. (نشرة موكسيبريل، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Methyldopa, Phenytoin and Carbamazepine Clinical Impact: Concomitant use may increase risk of adverse reactions of these drugs. (نشرة ليثيوم، التداخلات الدوائية)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (نشرة ليثيوم، التحذيرات والاحتياطات)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (نشرة نالبوفين، التداخلات الدوائية)

The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, tramadol, tryptophan, buspirone, and St. (نشرة ليثيوم، التحذيرات والاحتياطات)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (نشرة ليثيوم، التداخلات الدوائية)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (نشرة ليثيوم، التداخلات الدوائية)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (نشرة ليثيوم، التداخلات الدوائية)

Calcium Channel Blocking Agents (CCB) Clinical Impact: Concomitant use may increase the risk of neurologic adverse reactions in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus. (نشرة ليثيوم، التداخلات الدوائية)

• Encephalopathic Syndrome: Increased risk in patients treated with lithium and an antipsychotic. (نشرة ليثيوم، التحذيرات والاحتياطات)

• Diuretics, NSAID, renin-angiotensin system antagonists, or metronidazole may increase lithium serum concentrations. (نشرة ليثيوم، التداخلات الدوائية)

Drug Interactions: Concurrent use with lithium or antithyroid drugs may potentiate the hypothyroid and goitrogenic effects of these medications. (نشرة يوديد البوتاسيوم، التداخلات الدوائية)

Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (نشرة ليثيوم، التداخلات الدوائية)

Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (نشرة ليثيوم، التداخلات الدوائية)

Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Adverse Reaction ( 6.2)]. (نشرة أوكسيكودون وباراسيتامول، التداخلات الدوائية)

John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Drug Interactions ( 7.1 )]. (نشرة ليثيوم، التحذيرات والاحتياطات)

Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (نشرة ليثيوم، التداخلات الدوائية)

Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (نشرة ليثيوم، التداخلات الدوائية)

Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (نشرة ليثيوم، التداخلات الدوائية)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (نشرة فينترمين، التحذيرات والاحتياطات)

Lithium Co-administration of valproate (500 mg BID) and lithium carbonate (300 mg TID) to normal male volunteers (n = 16) had no effect on the steady-state kinetics of lithium. (نشرة حمض الفالبرويك، التداخلات الدوائية)